TUESDAY, Aug. 1 (HealthDay News) -- Some commercially available botulinum neurotoxin injections may be more painful than others, according to the results of a small study published in the July issue of Dermatologic Surgery.
Gottfried Kranz, M.D., of the Medical University of Vienna in Austria, and colleagues randomized 10 patients in a double-blind, controlled trial, so that each was injected with three commercially available treatments, as well as a saline control. The researchers reviewed levels of pain reported by the patients.
The investigators found that patients reported more pain with Neurobloc injections (botulinum neurotoxin type B) than saline or either Botox or Dysport (botulinum neurotoxin type A). There were no significant differences found between Dysport, Botox or saline, but they did find that less pain was reported with saline injections.
"Our data demonstrate that botulinum neurotoxin type B injections are associated with substantial pain. There is a considerable difference between the commercially available botulinum neurotoxin type B compared to the two botulinum neurotoxin type A preparations. Therefore, considering mitigation of injection pain seems necessary when using botulinum neurotoxin type B," the authors conclude.
The study was supported by the Medical University of Vienna.
Abstract
Full Text (subscription or payment may be required)
